Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be ...

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies into the clinic.

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET ...

In today’s fast-paced biotechnology landscape, AMSA Biotech emerges as a trailblazer in the field of regenerative medicine. Driven by a vision of science-led healing and personalized care, the company ...

IntroductionThe global mesenchymal stem cells market is witnessing a significant transformation as advancements in ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Bioengineers at Queen Mary University of London have taken a significant step forward in the development of laboratory-based ...

MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration ...

Researchers from the University of Oklahoma have made significant advances in a promising technology for efficient energy ...

"We're proud to be a Semifinalist team of XPRIZE Healthspan, a 7-year, $101 million global competition that aims to ...

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat ...